Development of antibody directed nanoparticles for cancer therapy

R. Ivkov, S. J. DeNardo, L. A. Meirs, A. Natarajan, Gerald L Denardo, C. Gruettner, A. R. Foreman

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The pharmacokinetics, tumor uptake, and biologic effects of inductively heating 111In-chimeric L6 (ChL6) monoclonal antibody (mAb)-linked iron oxide nanoparticle (bioprobes) by externally applied alternating magnetic fields (AMF) were studied in athymic mice bearing human breast cancer HBT 3477 xenografts. In addition, response was correlated with calculated total deposited heat dose. Methods: Using l-ethyl-3-(3-dimethylaminopropyl)-carbodiimideHCl, 111In-7,10-tetraazacyclododecane-N, N',N",N'"-tetraacetic acid-ChL6 was conjugated to the carboxylated polyethylene glycol on dextran-coated iron oxide 20-nm particles, one to two mAbs per nanoparticle. After magnetic purification and sterile filtration, pharmacokinetics, histopathology, and AMF/bioprobe therapy were done using 111In-ChL6 bioprobe doses (20 mcg/2.2 mg ChL6/ bioprobe), i.v. with 50 mcg ChL6 in athymic mice bearing HBT 3477; a 153 kHz AMF was given 72 hours postinjection for therapy with amplitudes of 1,300, 1,000, or 700 Oe. Weights, blood counts, and tumor size were monitored and compared with control mice receiving nothing, or AMF, or bioprobes alone. Results: 111In-ChL6 bioprobe binding in vitro to HBT 3477 cells was 50% to 70% of that of 111In-ChLo. At 48 hours, tumor, lung, kidney, and marrow uptakes of the 111In-ChL6 bioprobes were not different from that observed in prior studies of 111In-ChL6. Significant therapeutic responses from AMF/bioprobe therapy were shown compared with no treatment. In addition, greatest therapeutic benefit was observed for the 700 Oe treatment cohort. Toxicity was only seen in the 1,300 Oe AMF cohort, with 4 of 12 immediate deaths associated with skin erythema and petechiae. Conclusion: This study shows that mAb-conjugated nanoparticles (bioprobes), when given i.v., escape into the extravascular space and bind to cancer cell membrane antigen.Thus, bioprobes can be used in concert with externally applied AMF to deliver thermoablative cancer therapy. Therapeutic benefit was observed with increasing calculated heat dose deposited in tumors.

Original languageEnglish (US)
Title of host publicationThermal Treatment of Tissue: Energy Delivery and Assessment IV
Volume6440
DOIs
StatePublished - 2007
EventThermal Treatment of Tissue: Energy Delivery and Assessment IV - San Jose, CA, United States
Duration: Jan 20 2007Jan 21 2007

Other

OtherThermal Treatment of Tissue: Energy Delivery and Assessment IV
CountryUnited States
CitySan Jose, CA
Period1/20/071/21/07

Fingerprint

Antibodies
Magnetic fields
Nanoparticles
Tumors
Heterojunction bipolar transistors
Bearings (structural)
Monoclonal antibodies
Pharmacokinetics
Iron oxides
Dextran
Cell membranes
Antigens
Polyethylene glycols
Purification
Toxicity
Skin
Blood
Heating
Acids

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Ivkov, R., DeNardo, S. J., Meirs, L. A., Natarajan, A., Denardo, G. L., Gruettner, C., & Foreman, A. R. (2007). Development of antibody directed nanoparticles for cancer therapy. In Thermal Treatment of Tissue: Energy Delivery and Assessment IV (Vol. 6440). [64400I] https://doi.org/10.1117/12.710712

Development of antibody directed nanoparticles for cancer therapy. / Ivkov, R.; DeNardo, S. J.; Meirs, L. A.; Natarajan, A.; Denardo, Gerald L; Gruettner, C.; Foreman, A. R.

Thermal Treatment of Tissue: Energy Delivery and Assessment IV. Vol. 6440 2007. 64400I.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Ivkov, R, DeNardo, SJ, Meirs, LA, Natarajan, A, Denardo, GL, Gruettner, C & Foreman, AR 2007, Development of antibody directed nanoparticles for cancer therapy. in Thermal Treatment of Tissue: Energy Delivery and Assessment IV. vol. 6440, 64400I, Thermal Treatment of Tissue: Energy Delivery and Assessment IV, San Jose, CA, United States, 1/20/07. https://doi.org/10.1117/12.710712
Ivkov R, DeNardo SJ, Meirs LA, Natarajan A, Denardo GL, Gruettner C et al. Development of antibody directed nanoparticles for cancer therapy. In Thermal Treatment of Tissue: Energy Delivery and Assessment IV. Vol. 6440. 2007. 64400I https://doi.org/10.1117/12.710712
Ivkov, R. ; DeNardo, S. J. ; Meirs, L. A. ; Natarajan, A. ; Denardo, Gerald L ; Gruettner, C. ; Foreman, A. R. / Development of antibody directed nanoparticles for cancer therapy. Thermal Treatment of Tissue: Energy Delivery and Assessment IV. Vol. 6440 2007.
@inproceedings{ee7e4d145b4948b59344f533585e2356,
title = "Development of antibody directed nanoparticles for cancer therapy",
abstract = "The pharmacokinetics, tumor uptake, and biologic effects of inductively heating 111In-chimeric L6 (ChL6) monoclonal antibody (mAb)-linked iron oxide nanoparticle (bioprobes) by externally applied alternating magnetic fields (AMF) were studied in athymic mice bearing human breast cancer HBT 3477 xenografts. In addition, response was correlated with calculated total deposited heat dose. Methods: Using l-ethyl-3-(3-dimethylaminopropyl)-carbodiimideHCl, 111In-7,10-tetraazacyclododecane-N, N',N{"},N'{"}-tetraacetic acid-ChL6 was conjugated to the carboxylated polyethylene glycol on dextran-coated iron oxide 20-nm particles, one to two mAbs per nanoparticle. After magnetic purification and sterile filtration, pharmacokinetics, histopathology, and AMF/bioprobe therapy were done using 111In-ChL6 bioprobe doses (20 mcg/2.2 mg ChL6/ bioprobe), i.v. with 50 mcg ChL6 in athymic mice bearing HBT 3477; a 153 kHz AMF was given 72 hours postinjection for therapy with amplitudes of 1,300, 1,000, or 700 Oe. Weights, blood counts, and tumor size were monitored and compared with control mice receiving nothing, or AMF, or bioprobes alone. Results: 111In-ChL6 bioprobe binding in vitro to HBT 3477 cells was 50{\%} to 70{\%} of that of 111In-ChLo. At 48 hours, tumor, lung, kidney, and marrow uptakes of the 111In-ChL6 bioprobes were not different from that observed in prior studies of 111In-ChL6. Significant therapeutic responses from AMF/bioprobe therapy were shown compared with no treatment. In addition, greatest therapeutic benefit was observed for the 700 Oe treatment cohort. Toxicity was only seen in the 1,300 Oe AMF cohort, with 4 of 12 immediate deaths associated with skin erythema and petechiae. Conclusion: This study shows that mAb-conjugated nanoparticles (bioprobes), when given i.v., escape into the extravascular space and bind to cancer cell membrane antigen.Thus, bioprobes can be used in concert with externally applied AMF to deliver thermoablative cancer therapy. Therapeutic benefit was observed with increasing calculated heat dose deposited in tumors.",
author = "R. Ivkov and DeNardo, {S. J.} and Meirs, {L. A.} and A. Natarajan and Denardo, {Gerald L} and C. Gruettner and Foreman, {A. R.}",
year = "2007",
doi = "10.1117/12.710712",
language = "English (US)",
isbn = "0819465534",
volume = "6440",
booktitle = "Thermal Treatment of Tissue: Energy Delivery and Assessment IV",

}

TY - GEN

T1 - Development of antibody directed nanoparticles for cancer therapy

AU - Ivkov, R.

AU - DeNardo, S. J.

AU - Meirs, L. A.

AU - Natarajan, A.

AU - Denardo, Gerald L

AU - Gruettner, C.

AU - Foreman, A. R.

PY - 2007

Y1 - 2007

N2 - The pharmacokinetics, tumor uptake, and biologic effects of inductively heating 111In-chimeric L6 (ChL6) monoclonal antibody (mAb)-linked iron oxide nanoparticle (bioprobes) by externally applied alternating magnetic fields (AMF) were studied in athymic mice bearing human breast cancer HBT 3477 xenografts. In addition, response was correlated with calculated total deposited heat dose. Methods: Using l-ethyl-3-(3-dimethylaminopropyl)-carbodiimideHCl, 111In-7,10-tetraazacyclododecane-N, N',N",N'"-tetraacetic acid-ChL6 was conjugated to the carboxylated polyethylene glycol on dextran-coated iron oxide 20-nm particles, one to two mAbs per nanoparticle. After magnetic purification and sterile filtration, pharmacokinetics, histopathology, and AMF/bioprobe therapy were done using 111In-ChL6 bioprobe doses (20 mcg/2.2 mg ChL6/ bioprobe), i.v. with 50 mcg ChL6 in athymic mice bearing HBT 3477; a 153 kHz AMF was given 72 hours postinjection for therapy with amplitudes of 1,300, 1,000, or 700 Oe. Weights, blood counts, and tumor size were monitored and compared with control mice receiving nothing, or AMF, or bioprobes alone. Results: 111In-ChL6 bioprobe binding in vitro to HBT 3477 cells was 50% to 70% of that of 111In-ChLo. At 48 hours, tumor, lung, kidney, and marrow uptakes of the 111In-ChL6 bioprobes were not different from that observed in prior studies of 111In-ChL6. Significant therapeutic responses from AMF/bioprobe therapy were shown compared with no treatment. In addition, greatest therapeutic benefit was observed for the 700 Oe treatment cohort. Toxicity was only seen in the 1,300 Oe AMF cohort, with 4 of 12 immediate deaths associated with skin erythema and petechiae. Conclusion: This study shows that mAb-conjugated nanoparticles (bioprobes), when given i.v., escape into the extravascular space and bind to cancer cell membrane antigen.Thus, bioprobes can be used in concert with externally applied AMF to deliver thermoablative cancer therapy. Therapeutic benefit was observed with increasing calculated heat dose deposited in tumors.

AB - The pharmacokinetics, tumor uptake, and biologic effects of inductively heating 111In-chimeric L6 (ChL6) monoclonal antibody (mAb)-linked iron oxide nanoparticle (bioprobes) by externally applied alternating magnetic fields (AMF) were studied in athymic mice bearing human breast cancer HBT 3477 xenografts. In addition, response was correlated with calculated total deposited heat dose. Methods: Using l-ethyl-3-(3-dimethylaminopropyl)-carbodiimideHCl, 111In-7,10-tetraazacyclododecane-N, N',N",N'"-tetraacetic acid-ChL6 was conjugated to the carboxylated polyethylene glycol on dextran-coated iron oxide 20-nm particles, one to two mAbs per nanoparticle. After magnetic purification and sterile filtration, pharmacokinetics, histopathology, and AMF/bioprobe therapy were done using 111In-ChL6 bioprobe doses (20 mcg/2.2 mg ChL6/ bioprobe), i.v. with 50 mcg ChL6 in athymic mice bearing HBT 3477; a 153 kHz AMF was given 72 hours postinjection for therapy with amplitudes of 1,300, 1,000, or 700 Oe. Weights, blood counts, and tumor size were monitored and compared with control mice receiving nothing, or AMF, or bioprobes alone. Results: 111In-ChL6 bioprobe binding in vitro to HBT 3477 cells was 50% to 70% of that of 111In-ChLo. At 48 hours, tumor, lung, kidney, and marrow uptakes of the 111In-ChL6 bioprobes were not different from that observed in prior studies of 111In-ChL6. Significant therapeutic responses from AMF/bioprobe therapy were shown compared with no treatment. In addition, greatest therapeutic benefit was observed for the 700 Oe treatment cohort. Toxicity was only seen in the 1,300 Oe AMF cohort, with 4 of 12 immediate deaths associated with skin erythema and petechiae. Conclusion: This study shows that mAb-conjugated nanoparticles (bioprobes), when given i.v., escape into the extravascular space and bind to cancer cell membrane antigen.Thus, bioprobes can be used in concert with externally applied AMF to deliver thermoablative cancer therapy. Therapeutic benefit was observed with increasing calculated heat dose deposited in tumors.

UR - http://www.scopus.com/inward/record.url?scp=34548261273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548261273&partnerID=8YFLogxK

U2 - 10.1117/12.710712

DO - 10.1117/12.710712

M3 - Conference contribution

AN - SCOPUS:34548261273

SN - 0819465534

SN - 9780819465535

VL - 6440

BT - Thermal Treatment of Tissue: Energy Delivery and Assessment IV

ER -